N-(6-(pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide | 1192831-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N-(6-(pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide
• 英文别名: N-(6-pyridin-3-yl-1,3-benzothiazol-2-yl)acetamide；N-[6-(Pyridin-3-Yl)-1,3-Benzothiazol-2-Yl]acetamide
• CAS: 1192831-38-1
• 化学式: C₁₄H₁₁N₃OS
• 分子量: 269.327
• InChiKey: IRENWYOEYVTIRD-UHFFFAOYSA-N

物化性质

• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-6-溴苯并噻唑 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 反应 48.17h， 生成 N-(6-(pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide
  参考文献：
  名称：

  Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

  摘要：

  PI3 kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. The PI3 Kinase pathway is often de-regulated in cancer through PI3K alpha overexpression, gene amplification, mutations and PTEN phosphatase deletion. PI3K inhibitors represent therefore an attractive therapeutic modality for cancer treatment. Herein we describe how the potency of a benzothiazole fragment hit was quickly improved based on structural information and how this early chemotype was further optimized through scaffold hopping. This effort led to the identification of a series of 2-acetamido-5-heteroaryl imidazopyridines showing potent in vitro activity against all class I PI3Ks and attractive pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.010

文献信息

• [EN] FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS ET UTILISATIONS DE CEUX-CI COMME INHIBITEURS DE P13K
  申请人：MERCK SERONO SA

  公开号：WO2009133127A1

  公开（公告）日：2009-11-05

  The invention relates to compounds of formula (I), for the regulation of phosphoinositides 3-kinases activity and related diseases.

  这项发明涉及到式(I)的化合物，用于调节磷脂酰肌醇3-激酶的活性和相关疾病。
• [EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：MERCK SERONO SA

  公开号：WO2010100144A1

  公开（公告）日：2010-09-10

  The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

  该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物（I）的公式。
• PI3K/mTOR INHIBITORS
  申请人：Gong Xianchang

  公开号：US20110178070A1

  公开（公告）日：2011-07-21

  The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  该发明涉及公式如下的PI3K/mTOR抑制化合物：其中变量的定义如下。该发明还涉及包括此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该化合物的方法。
• PI3K/M TOR inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2311842A2

  公开（公告）日：2011-04-20

  Compounds of the formula: wherein ring A is heteroaryl, Q is O or S; L is selected from the group consisting of -CHR3-, -NR4- and -O-; X1 and X2 are each independently selected from the group consisting of CR5, and N; and R1, R2, R3, R4, R5 and R5' are defined herein, are provided. The compounds are P13K/mTOR inhibitors and are useful in the treatment of a number of conditions, including cancer and inflammatory diseases.

  式中的化合物： 其中环 A 是杂芳基，Q 是 O 或 S；L 选自 -CHR3-、-NR4- 和 -O- 组成的组；X1 和 X2 各自独立地选自 CR5 和 N 组成的组；以及 R1、R2、R3、R4、R5 和 R5' 在此定义。这些化合物是 P13K/mTOR 抑制剂，可用于治疗多种疾病，包括癌症和炎症性疾病。
• Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K
  作者：Sabina Pecchi、Zhi-Jie Ni、Wooseok Han、Aaron Smith、Jiong Lan、Matthew Burger、Hanne Merritt、Marion Wiesmann、John Chan、Susan Kaufman、Mark S. Knapp、Johanna Janssen、Kay Huh、Charles F. Voliva

  DOI：10.1016/j.bmcl.2013.06.010

  日期：2013.8

  PI3 kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. The PI3 Kinase pathway is often de-regulated in cancer through PI3K alpha overexpression, gene amplification, mutations and PTEN phosphatase deletion. PI3K inhibitors represent therefore an attractive therapeutic modality for cancer treatment. Herein we describe how the potency of a benzothiazole fragment hit was quickly improved based on structural information and how this early chemotype was further optimized through scaffold hopping. This effort led to the identification of a series of 2-acetamido-5-heteroaryl imidazopyridines showing potent in vitro activity against all class I PI3Ks and attractive pharmacokinetic properties. (C) 2013 Elsevier Ltd. All rights reserved.